Polaryx Therapeutics, Inc. Common Stock (PLYX) — Cash Flow-to-Debt Ratio
Polaryx Therapeutics, Inc. Common Stock (PLYX) has a Cash Flow-to-Debt Ratio of -1.57x as of June 2026, meaning its operating cash flow of $-1.37 Million could theoretically repay -2% of its total liabilities ($873.00K) in one year. See financial agility of Polaryx Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Polaryx Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for Polaryx Therapeutics, Inc. Common Stock across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Polaryx Therapeutics, Inc. Common Stock.
Annual Cash Flow-to-Debt Ratio for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
Year-by-year debt coverage analysis for Polaryx Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.61x | $-3.94 Million | $855.00K | ▲ +48.2% |
| 2024 | -8.90x | $-2.57 Million | $289.00K | ▼ -5241.9% |
| 2023 | -0.17x | $-173.00K | $1.04 Million | — |